Access to ELAHERE remains a top priority for Ovarian Cancer Canada. If you're a member of the Ovarian Cancer Canada mailing list, you should have received an email from us earlier today that invites you to help us urge decision-makers to restart negotiations that give Canadians access to this new treatment. Share your voice with your representative using our easy-to-use email tool!
By sending an email today, you can show decision-makers how important timely access to new treatments is for people living with ovarian cancer and their families. In just two minutes, you can call on your provincial or territorial decision-makers to help restart negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and the manufacturer so eligible patients can access ELAHERE as quickly as possible.
There are complex considerations involved in the negotiations to make new treatments, like ELAHERE, accessible in Canada, but the reality is simple: patients need access to this treatment now.
Patients and families have waited too long. They deserve better. Together, we can demand the change necessary to make this happen